Supraventricular tachycardias (SVTs) are among the most common cardiac arrhythmias encountered across the lifespan, contributing significantly to morbidity, reduced quality of life, and growing healthcare expenditures worldwide. The clinical diagnosis and management of SVTs have historically relied on electrophysiological mapping and the correlation of symptoms with rhythm abnormalities. However, recent research underscores the crucial role of genetic factors in shaping individual susceptibility, recurrence risk, and therapeutic responsiveness to SVTs. Advances in next-generation sequencing and genomics have substantially accelerated the identification of genetic variants associated with these arrhythmias and expanded opportunities for refined risk assessment and targeted therapeutic strategies.

Despite these scientific advances, the routine clinical integration of genetic findings remains limited by the need for robust validation, improved phenotype-genotype correlation, and the establishment of practical implementation pathways. Addressing these challenges will require collaborative, multidisciplinary research efforts aimed at bridging the gap between molecular discovery and clinical practice, ultimately enabling more precise and anticipatory patient care.

This Research Topic seeks to advance the understanding of the genetic underpinnings of SVTs and to drive the translation of genomic discoveries into tangible clinical applications. In view of the persistent challenges and the potential transformative impact of genomics, there is a pressing need to integrate both basic and translational insights to inform future diagnostic and management paradigms for SVT.

We invite submissions that comprehensively address molecular, clinical, and translational aspects of SVT genetics. We are particularly interested in studies that:
• Discover and functionally validate novel SVT-associated genes and genetic variants
• Explore innovations in genetic testing, including diagnostic yield and cost-effectiveness
• Assess the prognostic value of genetic markers for SVT recurrence and therapy response
• Integrate genomic data into risk stratification and clinical decision making for SVTs
• Investigate genotype-guided approaches in pharmacological and ablation therapies
• Examine ethical, economic, and implementation considerations surrounding clinical genomics in SVT care

Submissions leveraging data from human cohorts, translational models, or advanced in vitro systems, and applying high-throughput, scalable, and reproducible methodologies, are encouraged. Studies that bridge mechanistic insights with clinical endpoints, or that develop new models for SVT risk and management, will be particularly welcome.

We accept original research articles, systematic reviews, meta-analyses, and brief reports that significantly advance translational and clinical knowledge at the intersection of genetics and supraventricular tachycardias.

Are you interested in contributing a manuscript to this Research Topic?

Genetic Predictors of Supra-Ventricular Tachycardia: Pathways to Personalized Medicine